Latest Healthcare News

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

Promisia Healthcare reported a robust 29% increase in operating revenue for FY26, alongside a new dividend policy tied to operating free cash flow, setting the stage for continued growth in FY27.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Trajan Group Holdings reports steady market demand and successful cost initiatives in H2 FY26 but warns of a $4 million revenue hit from Australian dollar appreciation.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Skin Elements Limited has lodged an application with the Takeovers Panel alleging undisclosed voting power exceeding 20% via a private placement, raising questions about shareholder rights ahead of critical board spill meetings.

Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.